Altimmune Inc ALT Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Feb 02, 2024 (filed on Feb 05, 2024)

Insider Name:

Roberts M Scot

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Units

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-7,775

Price:

--
Feb 02, 2024 (filed on Feb 05, 2024)

Insider Name:

Roberts M Scot

Ownership Type:

Direct Ownership

Securities:

Common Stock, par value $0.0001

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-2,330

Price:

$9.32
Feb 02, 2024 (filed on Feb 05, 2024)

Insider Name:

Roberts M Scot

Ownership Type:

Direct Ownership

Securities:

Common Stock, par value $0.0001

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

7,775

Price:

--
Feb 02, 2024 (filed on Feb 05, 2024)

Insider Name:

Harris Matthew Scott

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Units

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-7,775

Price:

--
Feb 02, 2024 (filed on Feb 05, 2024)

Insider Name:

Harris Matthew Scott

Ownership Type:

Direct Ownership

Securities:

Common Stock, par value $0.0001

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-2,332

Price:

$9.32
Feb 02, 2024 (filed on Feb 05, 2024)

Insider Name:

Harris Matthew Scott

Ownership Type:

Direct Ownership

Securities:

Common Stock, par value $0.0001

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

7,775

Price:

--
Feb 02, 2024 (filed on Feb 05, 2024)

Insider Name:

Garg Vipin K

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Units

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-18,950

Price:

--
Feb 02, 2024 (filed on Feb 05, 2024)

Insider Name:

Garg Vipin K

Ownership Type:

Direct Ownership

Securities:

Common Stock, par value $0.0001

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-8,376

Price:

$9.32
Feb 02, 2024 (filed on Feb 05, 2024)

Insider Name:

Garg Vipin K

Ownership Type:

Direct Ownership

Securities:

Common Stock, par value $0.0001

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

18,950

Price:

--
Feb 01, 2024 (filed on Feb 05, 2024)

Insider Name:

Roberts M Scot

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Units

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-6,166

Price:

--

Filings by filing date

Feb 02, 2024 (filed on Feb 05, 2024)

Insider Name:

Roberts M Scot

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Units

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-7,775

Price:

--
Feb 01, 2024 (filed on Feb 05, 2024)

Insider Name:

Roberts M Scot

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Units

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-6,166

Price:

--
Feb 02, 2024 (filed on Feb 05, 2024)

Insider Name:

Roberts M Scot

Ownership Type:

Direct Ownership

Securities:

Common Stock, par value $0.0001

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-2,330

Price:

$9.32
Feb 02, 2024 (filed on Feb 05, 2024)

Insider Name:

Roberts M Scot

Ownership Type:

Direct Ownership

Securities:

Common Stock, par value $0.0001

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

7,775

Price:

--
Feb 01, 2024 (filed on Feb 05, 2024)

Insider Name:

Roberts M Scot

Ownership Type:

Direct Ownership

Securities:

Common Stock, par value $0.0001

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-1,801

Price:

$9.88
Feb 01, 2024 (filed on Feb 05, 2024)

Insider Name:

Roberts M Scot

Ownership Type:

Direct Ownership

Securities:

Common Stock, par value $0.0001

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

6,166

Price:

--
Feb 02, 2024 (filed on Feb 05, 2024)

Insider Name:

Harris Matthew Scott

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Units

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-7,775

Price:

--
Feb 01, 2024 (filed on Feb 05, 2024)

Insider Name:

Harris Matthew Scott

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Units

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-6,166

Price:

--
Feb 02, 2024 (filed on Feb 05, 2024)

Insider Name:

Harris Matthew Scott

Ownership Type:

Direct Ownership

Securities:

Common Stock, par value $0.0001

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-2,332

Price:

$9.32
Feb 02, 2024 (filed on Feb 05, 2024)

Insider Name:

Harris Matthew Scott

Ownership Type:

Direct Ownership

Securities:

Common Stock, par value $0.0001

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

7,775

Price:

--

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	910 Clopper Rd Ste 201S GAITHERSBURG MD 20878-1361
Tel:	N/A
Website:	https://altimmune.com
IR:	See website

Key People

Vipin K. Garg President, Chief Executive Officer, Director	Richard I. Eisenstadt Chief Financial Officer	M. Scot Roberts Chief Scientific Officer
M. Scott Harris Chief Medical Officer	Raymond M. Jordt Chief Business Officer

Business Overview

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Company's wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

Financial Overview

For the fiscal year ended 31 December 2023, Altimmune Inc revenues increased from -$68K to $426K. Net loss increased 4% to $88.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects R&D of immunotherapies and vaccines segment loss increase of 9% to $95.9M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.81 to -$1.66.

Employees:	59 as of Dec 31, 2023

Reporting Currency:	U.S. Dollars
Enterprise value:	$331.77M as of Dec 31, 2023
Annual revenue (TTM):	$0.43M as of Dec 31, 2023
EBITDA (TTM):	-$83.03M as of Dec 31, 2023
Net annual income (TTM):	-$88.45M as of Dec 31, 2023
Free cash flow (TTM):	-$75.86M as of Dec 31, 2023
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	70,895,286 as of Mar 22, 2024
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization